» Articles » PMID: 10852264

Do Lupus Disease Activity Measures Detect Clinically Important Change?

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 2000 Jun 14
PMID 10852264
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: New scales for the clinical assessment of patients with systemic lupus erythematosus (SLE) are valid and reliable, and quantitate disease activity. We assessed the responsiveness to change of 2 widely used standardized multi-item lupus activity measures, the revised Systemic Lupus Activity Measure (SLAM-R) and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and their ability to detect clinically relevant changes.

Methods: Ninety-six (96) patients with definite SLE participated in this study. The group mean age was 45.0 (13.7) years, 91% were female, and the mean disease duration was 14.9 (7.5) years. Sociodemographic information, lupus activity (SLAM-R, SLEDAI), and damage were recorded at baseline. At each of the 5 monthly followup visits, the activity measures were repeated and a transition scale asked the physician if their patient's lupus activity had changed. Five different methods were used to compare the responsiveness of the activity measures studied: 1. the effect size; 2. the standardized response mean; 3. the control standardized response mean; 4. the area under the curve of a receiver operating characteristic (ROC) curve; and 5. a new multiple response modeling approach.

Results: Both SLAM-R and SLEDAI are responsive. SLAM-R is consistently, although moderately, more responsive than SLEDAI. All 5 methods of evaluating responsiveness yielded a consistent ranking of disease activity measures.

Conclusion: SLAM-R and SLEDAI are responsive measures of lupus activity. SLAM-R appears to be more responsive than SLEDAI.

Citing Articles

Clinical Predictors of Mood Disorders and Prevalence of Neuropsychiatric Symptoms in Patients with Systemic Lupus Erythematosus.

Recio-Barbero M, Cabezas-Garduno J, Varona J, Ruiz-Irastorza G, Horrillo I, Meana J J Clin Med. 2024; 13(18).

PMID: 39336910 PMC: 11432540. DOI: 10.3390/jcm13185423.


SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus.

von Stuckrad S, Klotsche J, Biesen R, Lieber M, Thumfart J, Meisel C Lupus. 2020; 29(14):1914-1925.

PMID: 33081587 PMC: 7684796. DOI: 10.1177/0961203320965699.


Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study.

Fatemi A, Raeisi A, Sayedbonakdar Z, Smiley A Clin Rheumatol. 2017; 37(4):955-962.

PMID: 29256112 DOI: 10.1007/s10067-017-3949-2.


Subclinical cerebrovascular cognitive function, and mood changes in patients with systemic lupus erythematosus.

Shehata G, Abdel-Kareem M, Yassin A, El Adl A Open Access Rheumatol. 2010; 2:17-25.

PMID: 27789993 PMC: 5074773. DOI: 10.2147/oarrr.s9711.


Approaches for estimating minimal clinically important differences in systemic lupus erythematosus.

Rai S, Yazdany J, Fortin P, Avina-Zubieta J Arthritis Res Ther. 2015; 17:143.

PMID: 26036334 PMC: 4453215. DOI: 10.1186/s13075-015-0658-6.